Ballard Spahr has expanded its New York office with the addition of Lily Wound as a partner in its business and transactions department. Announced on Thursday, Wound joins the corporate group and the life sciences industry team at the firm. Her expertise lies in advising companies on complex commercial, licensing, and intellectual property-related transactions within the life sciences sector. Wound’s role extends to transactions throughout the lifecycle of life sciences products, from early-stage development to commercialization, encompassing areas such as artificial intelligence, gene therapy, gene editing, and engineered cell therapies. The firm highlighted her extensive experience and specialized knowledge as key assets in enhancing their capabilities in these critical sectors.
In a statement, Ballard Spahr expressed optimism about Wound’s impact, noting her ability to guide companies through the intricate transactions associated with innovative life sciences products. The legal landscape in which Wound operates is one characterized by rapid technological advancements and evolving regulatory requirements, making her insights particularly valuable. For more details on her role and the firm’s announcement, see the full story at Bloomberg Law.